Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report - PubMed (original) (raw)
Practice Guideline
. 2021 Dec;160(6):e545-e608.
doi: 10.1016/j.chest.2021.07.055. Epub 2021 Aug 2.
Scott C Woller 2, Lisa Baumann Kreuziger 3, Henri Bounameaux 4, Kevin Doerschug 5, Geert-Jan Geersing 6, Menno V Huisman 7, Clive Kearon 1, Christopher S King 8, Andrew J Knighton 9, Erica Lake 10, Susan Murin 11, Janine R E Vintch 12, Philip S Wells 13, Lisa K Moores 14
Affiliations
- PMID: 34352278
- DOI: 10.1016/j.chest.2021.07.055
Practice Guideline
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Scott M Stevens et al. Chest. 2021 Dec.
Erratum in
- Errata to: CHEST 2021;160(6):2247-2259 and CHEST 2021;160(6):e545-e608.
[No authors listed] [No authors listed] Chest. 2022 Jul;162(1):269. doi: 10.1016/j.chest.2022.05.028. Chest. 2022. PMID: 35809930 No abstract available.
Abstract
Background: This is the 2nd update to the 9th edition of these guidelines. We provide recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions, four of which have not been addressed previously.
Methods: We generate strong and weak recommendations based on high-, moderate-, and low-certainty evidence, using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology.
Results: The panel generated 29 guidance statements, 13 of which are graded as strong recommendations, covering aspects of antithrombotic management of VTE from initial management through secondary prevention and risk reduction of postthrombotic syndrome. Four new guidance statements have been added that did not appear in the 9th edition (2012) or 1st update (2016). Eight statements have been substantially modified from the 1st update.
Conclusion: New evidence has emerged since 2016 that further informs the standard of care for patients with VTE. Substantial uncertainty remains regarding important management questions, particularly in limited disease and special patient populations.
Keywords: DVT; antithrombotic therapy; guidelines; pulmonary embolism; thrombosis.
Copyright © 2021. Published by Elsevier Inc.
Similar articles
- Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Stevens SM, et al. Chest. 2021 Dec;160(6):2247-2259. doi: 10.1016/j.chest.2021.07.056. Epub 2021 Aug 2. Chest. 2021. PMID: 34352279 - Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021.
Stevens SM, Woller SC, Baumann Kreuziger L, Doerschug K, Geersing GJ, Klok FA, King CS, Murin S, Vintch JRE, Wells PS, Wasan S, Moores LK. Stevens SM, et al. Chest. 2024 Aug;166(2):388-404. doi: 10.1016/j.chest.2024.03.003. Epub 2024 Mar 6. Chest. 2024. PMID: 38458430 Review. - Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Kearon C, et al. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. Chest. 2016. PMID: 26867832 - Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Kearon C, et al. Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658. Chest. 2008. PMID: 18574272 - Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Büller HR, et al. Chest. 2004 Sep;126(3 Suppl):401S-428S. doi: 10.1378/chest.126.3_suppl.401S. Chest. 2004. PMID: 15383479 Review.
Cited by
- Superficial Venous Thrombosis: A Comprehensive Review.
Mangiafico M, Costanzo L. Mangiafico M, et al. Healthcare (Basel). 2024 Feb 19;12(4):500. doi: 10.3390/healthcare12040500. Healthcare (Basel). 2024. PMID: 38391875 Free PMC article. Review. - Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG, Keegan SP, Droege ME, Dykes NJH, Ernst NE, Foertsch MJ, Makley AT, Mueller EW, Philpott CD, Srinivasan V, Winter JB, Goodman MD, Droege CA. Bradshaw PG, et al. Pharmacotherapy. 2022 Oct;42(10):780-791. doi: 10.1002/phar.2727. Epub 2022 Sep 23. Pharmacotherapy. 2022. PMID: 36073083 Free PMC article. - Dual Anticoagulation With Warfarin and Apixaban: A Case Report.
Parker K, Yonosko P, Pilkington D. Parker K, et al. Cureus. 2022 Sep 12;14(9):e29093. doi: 10.7759/cureus.29093. eCollection 2022 Sep. Cureus. 2022. PMID: 36249603 Free PMC article. - [Deep vein thrombosis and pulmonary embolism : Diagnosis and treatment].
Bauersachs R. Bauersachs R. Inn Med (Heidelb). 2022 Jun;63(6):601-611. doi: 10.1007/s00108-022-01349-1. Epub 2022 May 9. Inn Med (Heidelb). 2022. PMID: 35532801 Review. German. - Rebuttal From Dr David Jimenez et al.
Jimenez D, Rali P, Doerschug K. Jimenez D, et al. Chest. 2022 Jun;161(6):1453-1455. doi: 10.1016/j.chest.2022.01.038. Epub 2022 Mar 15. Chest. 2022. PMID: 35469672 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical